Led in the UK by the Surrey and Borders Partnership NHS Foundation Trust, the PrevenTRON study aims to recruit 1,600 participants aged 55 to 80 globally to determine whether intervening before memory loss or cognitive symptoms appear can delay or prevent the onset of dementia.
How the PrevenTRON Alzheimer’s Trial Screens Participants
Participants in the international trial undergo rigorous initial screening to confirm they display no memory problems before taking a blood test that measures p-tau217, a specific biomarker capable of predicting cognitive decline and the development of Alzheimer’s, according to The Guardian. Research cited by The Guardian indicates that individuals showing the highest levels of p-tau217 possess an estimated 78% chance of developing cognitive impairment within 10 years, and that blood tests measuring the biomarker can identify the disease with up to 95% accuracy. Those who meet the criteria and display elevated biomarker levels are randomly assigned to receive either trontinemab or a placebo over a study period expected to last four to six years, as reported by The Guardian.
Targeting Amyloid Plaques Before Symptoms Emerge
Unlike traditional therapies that manage symptoms after diagnosis, trontinemab directly targets amyloid plaques—toxic accumulations of amyloid protein that clump together in the brain, slowing down and eventually destroying brain cells, according to information from the Alzheimer’s Society published by the BBC. Previous trial results released by Roche demonstrate that trontinemab effectively clears these plaques. The Guardian noted that early research found the drug cleared amyloid plaques in nine out of 10 people with early-stage Alzheimer’s or mild cognitive impairment within 28 weeks, successfully removing a primary characteristic of the condition.
Shifting Focus From Treatment to Prevention
Professor Ramin Nilforooshan, consultant psychiatrist and chief investigator for the PrevenTRON trial at Surrey and Borders Partnership NHS Foundation Trust, emphasized the paradigm shift in dementia research. “For decades, research has focused on treating Alzheimer’s disease after symptoms appear,” Professor Nilforooshan told The Telegraph. “PrevenTRON addresses a different question—whether we can act earlier, before symptoms begin.” At the same time, investigators urged caution regarding the experimental nature of the medication. “I’m not saying this trial is magic. It’s an investigational medicine. We need to wait and see: will it work or not?” Professor Nilforooshan told The Telegraph.
Did You Know?
Alzheimer’s disease is estimated to develop inside the human brain up to 10 years before individuals typically seek medical treatment for memory problems, according to findings reported by The Guardian. The condition affects approximately one in 14 people over the age of 65 in the UK, rising to one in six people over the age of 80, based on NHS data cited by the BBC.
Frequently Asked Questions
What is the PrevenTRON trial?
The PrevenTRON study is an international clinical trial evaluating whether the experimental drug trontinemab can stop or prevent the development of Alzheimer’s disease in healthy adults who have elevated biomarkers but no current symptoms of memory loss, according to The Guardian and the BBC.
Who is eligible to participate in the UK trial?
Healthy adults aged 55 to 80 who undergo screening to confirm they lack memory problems and test positive for elevated levels of the p-tau217 biomarker may be eligible, according to reports by the BBC and The Guardian. At least 15 hospitals and clinics across the UK are expected to participate by the end of the year.
How does trontinemab work?
Delivered directly into the vein via an IV bag, trontinemab targets and clears amyloid plaques—toxic protein clumps that damage and kill brain cells—according to the Alzheimer’s Society and Roche data cited in news reports.
To stay informed on major developments in medical research and public health trials, subscribe to our free Health Check email for exclusive weekly analysis.
Keep reading